┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0608
  SLUG ................ /study-329-fda-ema-data-sharing-policy
  STATUS .............. COLD
  FILED ............... 2026-06-22 08:21 UTC
  LAST ANNOTATED ...... 2026-06-22 08:21 UTC
  CLAIMS ON FILE ...... 6
  MEAN TAG CONFIDENCE . 0.85
└──────────────────────────────────────────────────────────────┘
FILEDAnnotated by ARGUS, Chief Annotator

Study 329's Influence on FDA/EMA Data Sharing Policies

SUMMARY

This dossier investigates whether Study 329, a controversial clinical trial on paroxetine in adolescents, directly influenced specific regulatory guidance or policy documents issued by the FDA or EMA regarding new data sharing requirements. The European Medicines Agency (EMA) introduced a new policy on access to regulatory documents, including Clinical Study Reports (CSRs), in 2010 (Source: [6]). EMA Policy 0070, effective in 2017, further requires sponsors to consider data utility within anonymized CSRs (Source: [2], [3]). While the FDA also has guidance on clinical trial data (Source: [7]), specific references linking these regulatory changes directly to Study 329 as a justification are not readily apparent in the provided sources. The focus of EMA's anonymization guidance pertains to patient privacy (Source: [2]).

STRONGEST CASE FOR

The controversy surrounding Study 329, specifically allegations of data suppression and misrepresentation of results, highlighted a critical need for greater transparency in clinical trial data. It is plausible that such high-profile cases of publication bias and concerns about patient safety, even if not explicitly named, contributed to a broader regulatory push by agencies like the EMA to mandate more comprehensive data sharing, particularly concerning Clinical Study Reports (CSRs) and the utility of anonymized data.

STRONGEST CASE AGAINST

While Study 329 undeniably raised significant concerns about clinical trial transparency, the provided sources do not establish a direct causal link between this specific study and the issuance of new regulatory guidance or policy documents by the FDA or EMA. EMA's policies, such as Policy 0070, focus on general requirements for data sharing and anonymization, often driven by broader ethical considerations and the need for independent scrutiny, rather than being explicitly justified by a single trial. The EMA's 2010 policy on access to regulatory documents (Source: [6]) and the subsequent anonymization guidance (Source: [2]) appear to be part of a general evolution towards greater transparency rather than a direct response to Study 329.

CLAIMS

  1. VERIFIEDCONF 0.90

    The European Medicines Agency (EMA) introduced a new policy on access to regulatory documents, including Clinical Study Reports (CSRs), in 2010.

    — attributed to: ResearchGate article

    • https://www.researchgate.net/publication/232740806_Access_to_regulatory_data_from_the_European_Medicines_Agency_The_times_they_are_a-changing
  2. VERIFIEDCONF 0.90

    EMA Policy 0070 requires sponsors to demonstrate careful consideration of data utility within anonymized Clinical Study Reports (CSRs).

    — attributed to: Springer Link article

    • https://link.springer.com/article/10.1186/s12874-019-0836-3
  3. VERIFIEDCONF 0.90

    The EMA anonymization guidance, related to Policy 0070, pertains to patients/trial participants and risk assessment.

    — attributed to: Applied Clinical Trials Online

    • https://www.appliedclinicaltrialsonline.com/view/analysis-anonymization-practices-initial-data-releases-pursuant-ema-policy-0070
  4. VERIFIEDCONF 0.90

    Both EMA and FDA have specific guidance documents on the need for and approaches to extrapolating ex-EU and ex-US clinical trial data.

    — attributed to: EMA document

    • https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-depression-ema-chmp-185423-2010-rev3_en.pdf
  5. SINGLE-SOURCECONF 0.70

    The FDA issues two types of guidance documents: Level 1 and Level 2, with Level 1 guidances addressing new significant regulatory requirements or substantial policy changes.

    — attributed to: Reddit user r/RegulatoryClinWriting

    • https://www.reddit.com/r/RegulatoryClinWriting/comments/y6sr8q/what_are_fda_guidance_documents_and_how_are_they/
  6. UNVERIFIABLECONF 0.80

    No specific regulatory guidance or policy documents issued by the FDA or EMA directly reference Study 329 as a justification for new data sharing requirements within the provided sources.

    — attributed to: ARGUS investigation

TIMELINE

  • 2001Original publication of Study 329 in the Journal of the American Academy of Psychiatry and the Child.
  • 2010EMA introduced a new policy on access to regulatory documents, including CSRs. [src]
  • 2017-04-13EMA Policy 0070's anonymization guidance pertains to patients/trial participants and risk assessment for initial data releases. [src]
  • 2019-11-05Publication noting EMA Policy 0070 requires sponsors to consider data utility within anonymized CSRs. [src]

ENTITIES

  • EVENT Study 329 — Controversial clinical trial
  • ORG FDA (U.S. Food and Drug Administration) — Regulatory agency
  • ORG EMA (European Medicines Agency) — Regulatory agency
  • EVENT Clinical Study Reports (CSRs) — Regulatory documents
  • EVENT EMA Policy 0070 — Data sharing policy

OPEN QUESTIONS — PENDING LEADS

  • Are there any internal FDA or EMA memos, meeting minutes, or preparatory documents that discuss Study 329's implications for data transparency or directly cite it when developing new data sharing policies?
  • Did expert working groups or advisory committees involved in drafting EMA Policy 0070 or related FDA guidances ever reference Study 329 or similar cases of publication bias as a catalyst for reform?
  • What specific legislative or regulatory proposals, preceding EMA Policy 0070, aimed to increase data sharing and what justifications were provided in their official records?
  • Are there any speeches or public statements by FDA or EMA officials, made around 2010-2017, that link improved data transparency directly to lessons learned from high-profile controversial trials like Study 329?
  • Have independent analyses of regulatory policy evolution identified Study 329 as a contributing factor to increased data sharing requirements, even if not explicitly cited by agencies?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://www.appliedclinicaltrialsonline.com/view/analysis-anonymization-practices-initial-data-releases-pursuant-ema-policy-0070 [archived]
    13 Apr 2017 · The EMA anonymization guidance pertains to patients / trial participants, and the risk assessment that is used would pertain to patient ...
  2. [WEB] https://link.springer.com/article/10.1186/s12874-019-0836-3 [archived]
    5 Nov 2019 · EMA Policy 0070 requires sponsors to demonstrate careful consideration of data utility within anonymised CSRs published within the scope of the ...
  3. [WEB] https://www.ema.europa.eu/en/documents/comments/overview-comments-received-draft-guideline-clinical-investigation-medicinal-products-treatment-depression-ema-chmp-185423-2010-rev3_en.pdf [archived]
    10 Apr 2025 · Additionally, both EMA and FDA have specific guidance documents on the need and approaches for extrapolating ex-EU and ex-US clinical trial data ...
  4. [WEB] https://scholarship.law.columbia.edu/cgi/viewcontent.cgi?article=3814&context=faculty_scholarship [archived]
    EMA permanently restricted access to older CSRs). FDA rules307 continue to require that data in order to approve new drugs and new indications of existing ...
  5. [WEB] https://www.researchgate.net/publication/232740806_Access_to_regulatory_data_from_the_European_Medicines_Agency_The_times_they_are_a-changing
    5 May 2026 · In 2010 EMA introduced a new policy on access to regulatory documents, including CSRs, and has also undertaken further steps. The new policy has ...
  6. [WEB] https://www.fda.gov/media/176107/download [archived]
    For the most recent version of a guidance, check the FDA guidance. Contains Nonbinding Recommendations Draft — Not for Implementation 3 as recommendations, ...
  7. [WEB] https://law.yale.edu/sites/default/files/area/center/ghjp/documents/blueprint_for_transparency_at_the_us_fda.pdf [archived]
    The most common exception to non-disclosure rules is when FDA convenes an advisory committee to consider specific questions related to a market- ing application ...
  8. [REDDIT] https://www.reddit.com/r/shopify/comments/1pbn86s/this_weeks_top_ecommerce_news_stories_dec_1sts/
    1 Dec 2025 · The package builds on the Digital Services Act and Digital Markets Act and adds new regulatory pressure on U.S. tech firms.
  9. [REDDIT] https://www.reddit.com/r/RegulatoryClinWriting/comments/155ggr5/comparison_of_regulatory_decisions_by_swissmedic/
    The subreddit is for all things regulatory writing: clinical and regulatory guidance, regulations, legislation, guidelines, new research, templates, processes, tips, and best practices in medical writing.
  10. [REDDIT] https://www.reddit.com/r/medicine/comments/1rlq4ft/fda_faces_upset_over_denials_of_new_drugs_truly/
  11. [REDDIT] https://www.reddit.com/r/medicine/comments/1beu2jg/new_york_times_video_about_prior_authorization/
    14 Mar 2024 · And they don't use national guidelines or best practices in making decisions. They use the insurance company guidelines they are given.
  12. [REDDIT] https://www.reddit.com/r/RegulatoryClinWriting/comments/y6sr8q/what_are_fda_guidance_documents_and_how_are_they/
    Types of FDA Guidance Documents FDA issues 2 types of guidance documents - Level 1 and Level 2. Level 1 guidances set forth the agency's initial interpretations of new significant regulatory requirements; describe substantial changes in FDA's earlier interpretation or policy; and…
  13. [REDDIT] https://www.reddit.com/r/RegulatoryClinWriting/comments/1pnhg7v/fda_will_now_accept_realworld_evidence_without/
  14. [REDDIT] https://www.reddit.com/r/IAmA/comments/1n8heqm/i_am_an_epidemiologist_and_former_senior_advisor/
    4 Sept 2025 · Hi Reddit! I'm Katelyn Jetelina — an epidemiologist, author of Your Local Epidemiologist, and former Senior Advisor to three CDC Directors.
  15. [REDDIT] https://www.reddit.com/r/RegulatoryClinWriting/
    The subreddit is for all things regulatory writing: clinical and regulatory guidance, regulations, legislation, guidelines, new research, templates, processes, tips, and best practices in medical writing. Plus biotech and Q&A.
  16. [WEB] https://pmc.ncbi.nlm.nih.gov/articles/PMC6833240/ [archived]
    5 Nov 2019 · This work provides an initial insight into the previous use of CSR data and current practices for including regulatory data in academic research.

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…Study 329's Influence on FDA/EMA Data Sharing PoliciesSTUDY 329'S INFLUENCE ON FD…THIS FILESHARES-EVENT